🇺🇸 FDA
Patent

US 11021710

Compounds and methods for reducing FXI expression

granted A61KA61K31/70A61K31/7088

Quick answer

US patent 11021710 (Compounds and methods for reducing FXI expression) held by Ionis Pharmaceuticals, Inc. expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/70, A61K31/7088